Fine epitope specificity of antibodies against interleukin-2 explains their paradoxical immunomodulatory effects

mAbs

Volumn 6, Issue 1, 2014, Pages 273-285

  Rojas, Gertrudis ^a   Infante, Yanelys Cabrera ^a   Pupo, Amaury ^a   Carmenate, Tania ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Cytokine; Epitope mapping; Immune complexes; Interleukin 2 receptor; Peptide library; Phage display; Site directed mutagenesis

Indexed keywords

EPITOPE; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY JES6 1A12; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL EXPANSION; COMPETITIVE INHIBITION; CONTROLLED STUDY; EFFECTOR CELL; EPITOPE MAPPING; HUMAN; IMMUNOMODULATION; MOUSE; MUTATION; NONHUMAN; PHAGE DISPLAY; REGULATORY T LYMPHOCYTE; SCREENING;

EID: 84892623310     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27224     Document Type: Article

References (38)

1. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4:665-74; PMID:15343366; http://dx.doi. org/10.1038/nri1435 (Pubitemid 39223073)
2. Hoyer KK, Dooms H, Barron L, Abbas AK. Interleukin-2 in the development and control of inflammatory disease. Immunol Rev 2008; 226:19-28; PMID:19161413; http://dx.doi. org/10.1111/j.1600-065X.2008.00697.x
3. Liao W, Lin J-X, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38:13-25; PMID:23352221; http://dx.doi.org/10.1016/j. immuni.2013.01.004
4. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24:1169-77; PMID:16505437; http://dx.doi.org/10.1200/ JCO.2005.03.6830 (Pubitemid 46638815)
5. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311:1924-7; PMID:16484453; http://dx.doi. org/10.1126/science.1122927
6. Kamimura D, Sawa Y, Sato M, Agung E, Hirano T, Murakami M. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J Immunol 2006; 177:306-14; PMID:16785526 (Pubitemid 43939142)
7. Mostböck S, Lutsiak ME, Milenic DE, Baidoo K, Schlom J, Sabzevari H. IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8+ T cell responses and increases the ratio of effector/memory CD8+ T cells to regulatory T cells. J Immunol 2008; 180:5118-29; PMID:18354238
8. Tomala J, Chmelova H, Mrkvan T, Rihova B, Kovar M. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. J Immunol 2009; 183:4904-12; PMID:19801515; http://dx.doi.org/10.4049/ jimmunol.0900284
9. Kohyama K, Sugiura H, Kozawa E, Wasa J, Yamada K, Nishioka A, Kamei Y, Taguchi O. Antitumor activity of an interleukin-2 monoclonal antibody in a murine osteosarcoma transplantation model. Anticancer Res 2012; 32:779-82; PMID:22399592
10. Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, Surh CD, Grey ST, Sprent J. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet al.ografts without immunosuppression. J Exp Med 2009; 206:751-60; PMID:19332874; http://dx.doi.org/10.1084/ jem.20082824
11. Liu R, Zhou Q, La Cava A, Campagnolo DI, Van Kaer L, Shi F-D. Expansion of regulatory T cells via IL-2/ anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur J Immunol 2010; 40:1577-89; PMID:20352624; http://dx.doi.org/10. 1002/ eji.200939792
12. Liu C-L, Ye P, Yen BC, Miao CH. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmidmediated gene therapy. Mol Ther 2011; 19:1511-20; PMID:21468007; http://dx.doi.org/10.1038/ mt.2011.61
13. Lee S-Y, Cho M-L, Oh H-J, Ryu J-G, Park M-J, Jhun J-Y, Park M-K, Stone JC, Ju J-H, Hwang S-Y, et al. Interleukin-2/anti-interleukin-2 monoclonal antibody immune complex suppresses collageninduced arthritis in mice by fortifying interleukin-2/ STAT5 signalling pathways. Immunology 2012; 137:305-16; PMID:23167249; http://dx.doi. org/10.1111/imm.12008
14. Boyman O, Surh CD, Sprent J. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther 2006; 6:1323-31; PMID:17223740; http://dx.doi.org/10.1517/14712598.6. 12.1323 (Pubitemid 44875686)
15. Rojas G, Pupo A, Leon K, Avellanet J, Carmenate T, Sidhu S. Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: a versatile platform for fine epitope mapping. Immunobiology 2013; 218:105-13; PMID:22459271; http://dx.doi.org/10.1016/j.imbio.2012.02.009
16. Chasteen L, Ayriss J, Pavlik P, Bradbury AR. Eliminating helper phage from phage display. Nucleic Acids Res 2006; 34:e145; PMID:17088290; http:// dx.doi.org/10.1093/nar/gkl772
17. Buchli PJ, Wu Z, Ciardelli TL. The functional display of interleukin-2 on filamentous phage. Arch Biochem Biophys 1997; 339:79-84; PMID:9056236; http://dx.doi.org/10.1006/abbi.1996.9853 (Pubitemid 27209797)
18. Vispo NS, Callejo M, Ojalvo AG, Santos A, Chinea G, Gavilondo JV, Araña MJ. Displaying human interleukin-2 on the surface of bacteriophage. Immunotechnology 1997; 3:185-93; PMID:9358271; http://dx.doi.org/10.1016/S1380- 2933(97)00012-2 (Pubitemid 27470354)
19. Felici F, Castagnoli L, Musacchio A, Jappelli R, Cesareni G. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J Mol Biol 1991; 222:301-10; PMID:1720463; http://dx.doi. org/10.1016/0022-2836(91)90213-P (Pubitemid 121004008)
20. Deroo S, Muller CP. Antigenic and immunogenic phage displayed mimotopes as substitute antigens: applications and limitations. Comb Chem High Throughput Screen 2001; 4:75-110; PMID:11281827; http://dx.doi.org/10.2174/1386207013331309 (Pubitemid 32405670)
21. Menendez A, Scott JK. The nature of target-unrelated peptides recovered in the screening of phagedisplayed random peptide libraries with antibodies. Anal Biochem 2005; 336:145-57; PMID:15620878; http://dx.doi.org/10.1016/j.ab. 2004.09.048 (Pubitemid 40044722)
22. Saphire EO, Montero M, Menendez A, van Houten NE, Irving MB, Pantophlet R, Zwick MB, Parren PWHI, Burton DR, Scott JK, et al. Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J Mol Biol 2007; 369:696-709; PMID:17445828; http://dx.doi. org/10.1016/j.jmb.2007.01.060 (Pubitemid 46709912)
23. Vispo NS, Araña MJ, Chinea G, Ojalvo AG, Cesareni G. Characterization of epitopes on human interleukin-2 using phage displayed-peptide libraries: insights into antibody-peptide interactions. Hybridoma 1999; 18:251-5; PMID:10475239; http://dx.doi.org/10.1089/ 027245799315907 (Pubitemid 29404321)
24. Davies DR, Padlan EA, Sheriff S. Antibody-antigen complexes. Annu Rev Biochem 1990; 59:439-73; PMID:2197980; http://dx.doi.org/10.1146/annurev. bi.59.070190.002255
25. Braden BC, Poljak RJ. Structural features of the reactions between antibodies and protein antigens. FASEB J 1995; 9:9-16; PMID:7821765
26. Davies DR, Cohen GH. Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A 1996; 93:7-12; PMID:8552677; http://dx.doi. org/10.1073/pnas.93.1.7 (Pubitemid 26038095)
27. Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its ?, ?, and gammac receptors. Science 2005; 310:1159-63; PMID:16293754; http://dx.doi.org/10.1126/ science.1117893
28. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A 2006; 103:2788-93; PMID:16477002; http://dx.doi.org/10. 1073/ pnas.0511161103
29. Phelan JD, Orekov T, Finkelman FD. Cutting edge: mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies. J Immunol 2008; 180:44-8; PMID:18097002
30. Tomala J, Kovarova J, Kabesova M, Votavova P, Chmelova H, Dvorakova B, Rihova B, Kovar M. Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionally. ACS Chem Biol 2013; 8:871-6; PMID:23419043; http://dx.doi. org/10.1021/cb3007242
31. Carmenate T, Pacios A, Enamorado M, Moreno E, Garcia-Martínez K, Fuente D, León K. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J Immunol 2013; 190:6230-8; PMID:23677467; http://dx.doi.org/10. 4049/ jimmunol.1201895
32. García-Martínez K, León K. Modeling the role of IL2 in the interplay between CD4+ helper and regulatory T cells: studying the impact of IL2 modulation therapies. Int Immunol 2012; 24:427-46; PMID:22371423; http://dx.doi.org/10.1093/ intimm/dxr120
33. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010; 33:153-65; PMID:20732639; http://dx.doi.org/10.1016/j.immuni.2010.08.004
34. Nakamura M, Asao H, Takeshita T, Sugamura K. Interleukin-2 receptor heterotrimer complex and intracellular signaling. Semin Immunol 1993; 5:309-17; PMID:8260647; http://dx.doi.org/10.1006/ smim.1993.1037
35. Zurawski SM, Mosmann TR, Benedik M, Zurawski G. Alterations in the amino-terminal third of mouse interleukin 2: effects on biological activity and immunoreactivity. J Immunol 1986; 137:3354-60; PMID:2430019 (Pubitemid 17181713)
36. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222:581-97; PMID:1748994; http://dx.doi. org/10.1016/0022-2836(91)90498-U
37. Kunkel TA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A 1985; 82:488-92; PMID:3881765; http://dx.doi.org/10.1073/pnas.82.2.488 (Pubitemid 15128292)
38. Fellouse FA, Sidhu SS. Making antibodies in bacteria. In Making and using antibodies. A practical handbook. G.C. Howard, and M.R.Kaser, CRC Press, Boca Raton, Florida, 2007, pp 157-177.